Tvardi Therapeutics (NASDAQ:TVRD) Upgraded by Raymond James Financial to Outperform Rating

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by analysts at Raymond James Financial from a “market perform” rating to an “outperform” rating in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a $10.00 target price on the stock. Raymond James Financial’s price target indicates a potential upside of 222.58% from the stock’s current price.

A number of other equities analysts have also recently weighed in on TVRD. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 price target for the company in a report on Wednesday. HC Wainwright assumed coverage on Tvardi Therapeutics in a research report on Monday, June 8th. They issued a “buy” rating and a $9.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and set a $15.00 target price on shares of Tvardi Therapeutics in a research note on Tuesday. Wall Street Zen lowered Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tvardi Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $26.17.

Tvardi Therapeutics Price Performance

TVRD opened at $3.10 on Wednesday. The firm has a fifty day moving average price of $3.05 and a 200 day moving average price of $3.52. Tvardi Therapeutics has a 1 year low of $1.50 and a 1 year high of $43.65. The stock has a market cap of $29.08 million, a P/E ratio of -1.00 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). Equities analysts expect that Tvardi Therapeutics will post -2.39 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. American Financial Group Inc. acquired a new stake in shares of Tvardi Therapeutics in the fourth quarter valued at about $962,000. Vestal Point Capital LP purchased a new stake in Tvardi Therapeutics during the 3rd quarter valued at about $6,508,000. Geode Capital Management LLC purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at about $2,617,000. Invesco Ltd. acquired a new stake in Tvardi Therapeutics in the 3rd quarter valued at about $3,219,000. Finally, Renaissance Technologies LLC raised its holdings in Tvardi Therapeutics by 246.3% in the 4th quarter. Renaissance Technologies LLC now owns 104,500 shares of the company’s stock valued at $449,000 after acquiring an additional 74,325 shares during the last quarter. 44.66% of the stock is owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.